Pegaspargase
| Generic name | Pegaspargase |
| Pronunciation | peg-AS-par-jase |
| Brand name(s), other common name(s) | Oncaspar®, PEG-L-asparaginase |
| Drug type | Enzyme that prevents cancer cells from surviving |
| How the drug is given | Intravenously (IV) |
Pegaspargase is FDA approved in combination with other chemotherapy medications to treat people who have acute lymphoblastic leukemia (ALL).
Side effects needing medical attention:
Abdominal or stomach pain; blurry vision; constipation; dry mouth and skin; fatigue; increased hunger or thirst; increased need to urinate; nausea; rash; unexplained weight loss; vomiting.
For information on how to manage the costs of drug therapy, please see Financial Matters and Prescription Drug Coverage, or to speak with an Information Specialist, call (800) 955-4572.
